Industry Trends

Looking back at 1986-1989.

Tracing biopharma’s innovation evolution—and, framed by COVID-19 and the med-tech boon, a look at four notable efforts focused on that one elusive constant: translational value.

Agency faces a significant backlog in the US and abroad.

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.

Francesca Properzi and Sudip Sinha talk about how the results of an inaugural Clinical Trial Digital Tracker Survey indicate that many clinical trials organizations are still reluctant to integrate digital technologies into their processes.

Vaccine manufacturers anticipate significant boosts in output in the coming weeks.

Three changes manufacturers should consider in the wake of COVID-19.

Donald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.

R&D on medical treatments lags notable success with vaccines.

Looking back at 1982-1985.

Almost a year since the start of the pandemic, it’s clear a new medical vision is taking shape—one focused on serving patients now, solving procedural issues later.

A look at the results of recent surveys revealing the impact of the COVID-triggered digital switchover on sales rep interactions and medical conferences.

Telemedicine is definitely here to stay, but recent study may offer clues on its sustaining power.

Melissa Fellner of AstraZeneca and Leonie Goddard of Veeva, talk to Pharm Exec about how AZ’s mission to transform its digital strategies to better connect with customers.

*** Wednesday, February 3, 2021 at 1pm EST | 12pm CST | 10am PST*** Industry leading ERP & MRP Solutions for Pharma. Join our informative Webinar with AdaptaLogix, the fastest growing NetSuite & Oracle partner, to learn more about the solutions that have been developed to meet mid-market pharma’s unmet needs. ***On demand available after final airing until Feb. 3, 2022***

Laura Barrell, Senior Associate at VWV, outlines how the UK is emerging from the trials of Brexit and COVID to take a leading international role in the future of pharma and healthcare.

Cathy Traz of Bristol Myers Squibb outlines the mission of the COVID Advocacy Exchange, a virtual platform that convenes advocacy groups, patients, and industry for increased connection and collaboration.

The pharmaceutical industry must be prepared for the coming wave of COVID-related safety reports.

President Joe Biden has unveiled a lengthy program for combatting COVID-19 by ramping up distribution and inoculation of millions of Americans over the next three months.

The process of distributing millions of doses of new vaccines across the nation has been much less effective than anticipated.

With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.

Data suggests physicians just as hesitant as patients, but recent successes could turn the tide.

Looking back at 1981.

CDER's process for vetting and authorizing important new therapies remained strong and productive last year, despite the need to deal with COVID-19 related approvals and policies.

Applications put on hold as agency limits alternative oversight methods.

Donna L. LaVoie outlines the takeaways of a recent industry webinar discussing global trends on public and private markets, JPM virtual week, and more. 

President Trump finally signs the critical year-end COVID-19 package, appropriating $2.3 trillion to finance the federal government through September 2021 and providing critical support for individuals and entities suffering from the economic crisis wrought by the pandemic.

Jill Wechsler reports on FDA's newly published strategies supporting broader eligibility criteria for Phase III studies.

If the COVID-19 crisis represents an unprecedented opportunity for pharma to strengthen its public reputation, it also poses enormous risks if things go wrong, writes Professor Guido Palazzo.

FDA is poised to approve an Emergency Use Authorization (EUA) for the much anticipated vaccine against COVID-19 developed by Pfizer/BioNTech following a strong vote of support by the Agency's vaccine advisory committee